[go: up one dir, main page]

FI914534A0 - Nya sulfonamidantagonister foer fibrinogenreceptorer. - Google Patents

Nya sulfonamidantagonister foer fibrinogenreceptorer.

Info

Publication number
FI914534A0
FI914534A0 FI914534A FI914534A FI914534A0 FI 914534 A0 FI914534 A0 FI 914534A0 FI 914534 A FI914534 A FI 914534A FI 914534 A FI914534 A FI 914534A FI 914534 A0 FI914534 A0 FI 914534A0
Authority
FI
Finland
Prior art keywords
opt
substd
alkyl
aryl
het1
Prior art date
Application number
FI914534A
Other languages
English (en)
Other versions
FI914534L (fi
FI108295B (fi
Inventor
Mark E Duggan
Melissa S Egbertson
George D Hartman
Wasyl Halczenko
William L Laswell
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of FI914534A0 publication Critical patent/FI914534A0/fi
Publication of FI914534L publication Critical patent/FI914534L/fi
Application granted granted Critical
Publication of FI108295B publication Critical patent/FI108295B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • External Artificial Organs (AREA)
FI914534A 1990-09-27 1991-09-26 Menetelmä terapeuttisesti käyttökelpoisten sulfonamidoyhdisteiden valmistamiseksi FI108295B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58913090A 1990-09-27 1990-09-27
US75064791A 1991-08-30 1991-08-30

Publications (3)

Publication Number Publication Date
FI914534A0 true FI914534A0 (fi) 1991-09-26
FI914534L FI914534L (fi) 1992-03-28
FI108295B FI108295B (fi) 2001-12-31

Family

ID=27080454

Family Applications (2)

Application Number Title Priority Date Filing Date
FI914534A FI108295B (fi) 1990-09-27 1991-09-26 Menetelmä terapeuttisesti käyttökelpoisten sulfonamidoyhdisteiden valmistamiseksi
FI20011201A FI20011201L (fi) 1990-09-27 2001-06-06 Terapeuttisesti käyttökelpoisia sulfonamidoyhdisteitä

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20011201A FI20011201L (fi) 1990-09-27 2001-06-06 Terapeuttisesti käyttökelpoisia sulfonamidoyhdisteitä

Country Status (32)

Country Link
US (5) US5292756A (fi)
EP (2) EP0743302B1 (fi)
JP (2) JPH0794425B2 (fi)
KR (1) KR100216939B1 (fi)
CN (1) CN1038748C (fi)
AT (1) ATE150454T1 (fi)
AU (1) AU655436B2 (fi)
BG (1) BG61810B1 (fi)
CA (1) CA2052073C (fi)
CY (1) CY2048B1 (fi)
DE (2) DE69125235T2 (fi)
DK (1) DK0478363T3 (fi)
ES (2) ES2100214T3 (fi)
FI (2) FI108295B (fi)
GR (2) GR3023226T3 (fi)
HR (1) HRP930779B1 (fi)
IE (1) IE913383A1 (fi)
IL (1) IL99540A (fi)
LU (1) LU90505I2 (fi)
LV (1) LV12089B (fi)
NL (1) NL990040I2 (fi)
NO (2) NO177702C (fi)
NZ (1) NZ239846A (fi)
PL (1) PL172687B1 (fi)
PT (1) PT99098B (fi)
RO (1) RO116621B1 (fi)
RU (1) RU2116296C1 (fi)
SI (1) SI9210306B (fi)
SK (1) SK281233B6 (fi)
UA (1) UA44222C2 (fi)
WO (1) WO1993019046A1 (fi)
YU (1) YU48912B (fi)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
US5645815A (en) * 1991-02-08 1997-07-08 Diatide, Inc. Radiolabled compounds for thrombus imaging
US5321034A (en) * 1991-05-07 1994-06-14 Merck & Co., Inc. Fibrinogen receptor antagonists
US5939412A (en) * 1992-06-26 1999-08-17 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
ES2190428T3 (es) * 1991-06-28 2003-08-01 Smithkline Beecham Corp Antagonistas biciclicos de fibrinogeno.
WO1993006106A1 (en) * 1991-09-24 1993-04-01 Janssen Pharmaceutica N.V. PROCESS FOR PREPARING ENANTIOMERICALLY PURE IMIDAZO[4,5,1-jk][1,4]-BENZODIAZEPIN-2(1H^_)-THIONES
US5264457A (en) * 1992-02-14 1993-11-23 G. D. Searle & Co. Phenyl amidines sulfonamides useful as platelet aggregation inhibitors
TW224462B (fi) * 1992-02-24 1994-06-01 Squibb & Sons Inc
US5312923A (en) * 1992-02-28 1994-05-17 Merck & Co., Inc. Process for preparing fibrinogen receptor antagonists
US5206373A (en) * 1992-02-28 1993-04-27 Merck & Co., Inc. Process for preparing fibrinogen receptor antagonists
US5504106A (en) * 1992-06-25 1996-04-02 G. D. Searle & Co. Phenyl amidine alkanoic acids and lactones useful as platelet aggregation inhibitors
WO1994008577A1 (en) * 1992-10-14 1994-04-28 Merck & Co., Inc. Fibrinogen receptor antagonists
ATE188379T1 (de) * 1992-10-14 2000-01-15 Merck & Co Inc Fibrinogenrezeptor-antagonisten
US5358956A (en) * 1992-10-14 1994-10-25 Merck & Co., Inc. Fibrinogen receptor antagonists
US5340798A (en) * 1992-10-14 1994-08-23 Merck & Co., Inc. Fibrinogen receptor antagonists
US5648368A (en) * 1992-12-01 1997-07-15 Merck & Co., Inc. Fibrinogen receptor antagonists
US5652242A (en) * 1993-03-29 1997-07-29 Zeneca Limited Heterocyclic derivatives
US5753659A (en) * 1993-03-29 1998-05-19 Zeneca Limited Heterocyclic compouds
US5556977A (en) * 1993-03-29 1996-09-17 Zeneca Limited Heterocyclic derivatives
US5750754A (en) * 1993-03-29 1998-05-12 Zeneca Limited Heterocyclic compounds
AU692439B2 (en) * 1993-03-29 1998-06-11 Zeneca Limited Heterocyclic compounds as platelet aggregation inhibitors
US5441952A (en) * 1993-04-05 1995-08-15 Merck & Co., Inc. Fibrinogen receptor antagonists
US5334596A (en) * 1993-05-11 1994-08-02 Merck & Co., Inc. Fibrinogen receptor antagonists
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
US6984627B1 (en) * 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
US5612355A (en) * 1993-06-23 1997-03-18 G. D. Searle & Co. Phenyl amidine lactones useful as platelet aggregation inhibitors
GB9313285D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Acid derivatives
GB9313268D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Chemical compounds
US5463011A (en) * 1993-06-28 1995-10-31 Zeneca Limited Acid derivatives
CA2166075A1 (en) * 1993-06-30 1995-01-12 Yoshiharu Ikeda Novel dipiperidine derivative
US5397791A (en) * 1993-08-09 1995-03-14 Merck & Co., Inc. Fibrinogen receptor antagonists
DE69426602T2 (de) * 1993-10-19 2001-08-30 Sumitomo Pharmaceuticals Co., Ltd. 2,3-diaminopropionsäurederivate
US5446056A (en) * 1993-11-24 1995-08-29 The Du Pont Merck Pharmaceutical Company Isoxazoline compounds useful as fibrinogen receptor antagonists
US5523302A (en) * 1993-11-24 1996-06-04 The Du Pont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
US5563158A (en) * 1993-12-28 1996-10-08 The Dupont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
MA23420A1 (fr) * 1994-01-07 1995-10-01 Smithkline Beecham Corp Antagonistes bicycliques de fibrinogene.
US5821241A (en) * 1994-02-22 1998-10-13 Merck & Co., Inc. Fibrinogen receptor antagonists
DE69528829T2 (de) * 1994-05-27 2003-08-07 Merck & Co., Inc. Präparate zur hemmung der durch osteoklasten vermittelten knochenresorption
US6458784B1 (en) 1994-06-29 2002-10-01 Smithkline Beecham Corporation Vitronectin receptor antagonists
US5451578A (en) * 1994-08-12 1995-09-19 Merck & Co., Inc. Fibrinogen receptor antagonists
US5525617A (en) * 1994-08-24 1996-06-11 Merck & Co., Inc. Fibrinogen receptor antagonists
US5494921A (en) * 1994-09-16 1996-02-27 Merck & Co., Inc. Fibrinogen receptor antagonists
EP0799189A4 (en) * 1994-12-13 1999-03-17 Smithkline Beecham Corp BICYCLIC FIBRINOGENIC ANTAGONISTS
WO1996019223A1 (en) * 1994-12-22 1996-06-27 Smithkline Beecham Corporation Fibrinogen receptor antagonists
US5719144A (en) * 1995-02-22 1998-02-17 Merck & Co., Inc. Fibrinogen receptor antagonists
ZA963391B (en) * 1995-05-24 1997-10-29 Du Pont Merck Pharma Isoxazoline fibrinogen receptor antagonists.
IL118007A0 (en) * 1995-05-24 1996-08-04 Du Pont Merck Pharma Isoxazoline compounds pharmaceutical compositions containing them and their use
US5977101A (en) * 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
US6100423A (en) * 1995-08-30 2000-08-08 G. D. Searle & Co. Amino benzenepropanoic acid compounds and derivatives thereof
RO118289B1 (ro) 1995-08-30 2003-04-30 Gd Searle & Co Chicago Derivati de fenilcarboniluree si compozitie farmaceutica
US5789421A (en) * 1995-10-26 1998-08-04 Merck & Co., Inc. Fibrinogen receptor antagonist
TW385248B (en) * 1995-10-27 2000-03-21 Merck & Co Inc Pharmaceutical compositions for intravenous administration for inhibiting platelet aggregation
US5733919A (en) * 1995-10-27 1998-03-31 Merck & Co., Inc. Compositions for inhibiting platelet aggregation
US5972967A (en) * 1996-10-23 1999-10-26 Merck & Co., Inc. Compositions for inhibiting platelet aggregation
DE19548709A1 (de) * 1995-12-23 1997-07-03 Merck Patent Gmbh Tyrosinderivate
US5952306A (en) * 1996-01-16 1999-09-14 Merck & Co., Inc. Integrin receptor antagonists
US5780480A (en) * 1996-02-28 1998-07-14 Merck & Co., Inc. Fibrinogen receptor antagonists
AU712082B2 (en) * 1996-02-28 1999-10-28 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1997035579A1 (en) * 1996-03-27 1997-10-02 Merck & Co., Inc. A method for inhibiting clot formation
PT894084E (pt) * 1996-03-29 2002-11-29 Searle & Co Derivados de acido cinamico e sua utilizacao como antagonistas de integrina
WO1997036859A1 (en) * 1996-03-29 1997-10-09 G.D. Searle & Co. Para-substituted phenylpropanoic acid derivatives as integrin antagonists
DE69705300T2 (de) * 1996-03-29 2002-05-02 G.D. Searle & Co., Chicago Cyclopropylalkansäurederivate
EP0889877B1 (en) * 1996-03-29 2001-08-29 G.D. Searle & Co. META-SUBSTITUTED PHENYLENE DERIVATIVES AND THEIR USE AS ALPHAvBETA3 INTEGRIN ANTAGONISTS OR INHIBITORS
DK0889876T3 (da) * 1996-03-29 2001-09-24 Searle & Co Meta-substituerede phenylensulfonamidderivater
CA2259487A1 (en) 1996-07-01 1998-01-08 Margaret Mary Faul Hypoglycemic and hypolipidemic compounds
US6653331B2 (en) * 1996-07-03 2003-11-25 Pharmacia & Upjohn Company Targeted drug delivery using sulfonamide derivatives
US5977138A (en) * 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
WO1998006707A1 (en) * 1996-08-15 1998-02-19 Dupont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
US6004955A (en) * 1996-08-15 1999-12-21 Dupont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as IIb/IIIa antagonists
US5900414A (en) * 1996-08-29 1999-05-04 Merck & Co., Inc. Methods for administering integrin receptor antagonists
US5978698A (en) * 1996-10-08 1999-11-02 Merck & Co., Inc. Angioplasty procedure using nonionic contrast media
EA002475B1 (ru) * 1996-11-27 2002-06-27 Авентис Фармасьютикалз Продактс Инк. Фармкомпозиция, содержащая соединения с анти-ха активностью и соединения антагониста агрегации тромбоцитов, их применение, набор, содержащий эти соединения, способ лечения или профилактики заболеваний, сопутствующих тромбообразованию
US5981584A (en) * 1997-02-06 1999-11-09 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
US6294549B1 (en) 1997-07-23 2001-09-25 Merck & Co., Inc. Method for eliciting an αvβ5 or dual αvβ3/αvβ5 antagonizing effect
EP1049693A1 (en) * 1997-11-26 2000-11-08 Du Pont Pharmaceuticals Company 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS $g(a) v?$g(b) 3? ANTAGONISTS
US6623981B2 (en) * 1998-01-27 2003-09-23 Bristol-Myers Squibb Company Detection of patients at risk for developing integrin antagonist/agonist mediated disease states
EP1053227B1 (en) 1998-01-29 2008-11-05 Amgen Inc. Ppar-gamma modulators
US6583157B2 (en) 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US6136794A (en) * 1998-02-02 2000-10-24 Merck & Co., Inc. Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
AU740941B2 (en) * 1998-02-02 2001-11-15 Correvio Llc Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
US6117842A (en) * 1998-03-09 2000-09-12 Merck & Co., Inc. Fibrinogen receptor antagonists
US6136804A (en) 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
AU3213799A (en) 1998-04-01 1999-10-18 Du Pont Pharmaceuticals Company Integrin antagonists
AU4584199A (en) 1998-06-29 2000-01-17 Du Pont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
JP2002528522A (ja) * 1998-11-04 2002-09-03 ロディア・シミ スルホニル化法およびパーハロゲン化スルファニリドの合成に有用な試薬
HK1045495A1 (zh) 1999-01-22 2002-11-29 依兰制药公司 抑制vla-4介导的白细胞粘着的多环化合物
HK1043794A1 (zh) 1999-01-22 2002-09-27 依兰制药公司 抑制vla-4介导的白细胞粘附的稠合环杂芳基和杂环化合物
US6479492B1 (en) * 1999-01-22 2002-11-12 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
KR100377558B1 (ko) * 1999-02-12 2003-03-26 주식회사 엘지생명과학 피페리딘 작용기를 갖는 선택적 트롬빈 억제제
KR100377557B1 (ko) * 1999-02-12 2003-03-26 주식회사 엘지생명과학 아실 구아니딘 작용기를 갖는 선택적 트롬빈 억제제
ATE264298T1 (de) 1999-03-01 2004-04-15 Elan Pharm Inc Alpha-aminoessigsäure derivate als alpha 4 beta 7-rezeptor antagonisten
US6348504B1 (en) 1999-03-30 2002-02-19 Richard E. Olson Oxime ethers as IIb/IIa antagonists
US7041691B1 (en) * 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
PT1235830E (pt) 1999-12-10 2004-04-30 Pfizer Prod Inc Compostos de pirrolo¬2,3-d|pirimidina como inibidores das proteina cinases
JP2003519120A (ja) * 1999-12-27 2003-06-17 オーソーマクニール ファーマシューティカル， インコーポレイテッド 卵胞刺激ホルモンの拮抗物質としての置換したアミノアルキルアミド誘導体
PL365444A1 (en) * 2000-03-21 2005-01-10 The Procter & Gamble Company Heterocyclic side chain containing, n-substituted metalloprotease inhibitors
US6653332B2 (en) 2000-05-03 2003-11-25 Tularik Inc. Combination therapeutic compositions and method of use
US20030171399A1 (en) * 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
IL154496A0 (en) * 2000-08-30 2003-09-17 Pharmacia Corp GEM-SUBSTITUTED alpha v beta3 INTEGRIN ANTAGONISTS
US7067539B2 (en) 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
US7507767B2 (en) 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
CA2449054C (en) * 2001-05-30 2011-01-04 The Scripps Research Institute Integrin targeting liposome for nucleic acid delivery
US7345068B2 (en) * 2002-02-07 2008-03-18 Hitoshi Endou Aromatic amino acid derivatives and medicinal compositions
US6770660B2 (en) * 2002-05-06 2004-08-03 Artery Llc Method for inhibiting platelet aggregation
TWI281470B (en) * 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
TW200307671A (en) * 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
CN100422147C (zh) * 2002-11-01 2008-10-01 北京天衡药物研究院 一种制备0-取代磺酰酪氨酸类化合物的方法
CN1738807A (zh) * 2002-11-15 2006-02-22 卡地拉健康护理有限公司 取代的芳烷基衍生物
CN101353321A (zh) * 2002-11-21 2009-01-28 辉瑞产品公司 3-氨基-哌啶衍生物及其制备方法
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US7504497B2 (en) * 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
US7335648B2 (en) * 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
EP1685135B1 (en) * 2003-10-21 2010-05-26 Inspire Pharmaceuticals, Inc. TETRAHYDRO-FURO[3,4-d]DIOXOLE COMPOUNDS AND COMPOSITIONS AND METHOD FOR INHIBITING PLATELET AGGREGATION
US7749981B2 (en) * 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
DE10356346A1 (de) * 2003-11-28 2005-06-23 TransMIT Gesellschaft für Technologietransfer mbH Erfindung betreffend Prophylaxe und Therapie von Erkrankungen, die durch Thrombusbildung verusacht oder mit versacht werden
JP2007527918A (ja) * 2004-03-08 2007-10-04 アムジェン インコーポレイテッド Ｐｐａｒガンマ活性の治療的調節
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
CN1330636C (zh) * 2005-09-26 2007-08-08 鲁南制药集团股份有限公司 盐酸替罗非班中间体的合成方法
CA2851103A1 (en) 2005-09-29 2007-04-12 Elan Pharmaceuticals, Inc. Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4
JP5101512B2 (ja) * 2005-09-29 2012-12-19 エラン ファーマシューティカルズ，インコーポレイテッド Ｖｌａ−４によって媒介される白血球接着を阻害するピリミジニルアミド化合物
WO2007101165A1 (en) * 2006-02-27 2007-09-07 Elan Pharmaceuticals, Inc. Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4
WO2008083491A1 (en) 2007-01-11 2008-07-17 Critical Outcome Technologies Inc. Compounds and method for treatment of cancer
US8138191B2 (en) 2007-01-11 2012-03-20 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
US20100297621A1 (en) * 2007-06-20 2010-11-25 University Of Utah Research Foundation Use of pre-mrna splicing in platelet cells for the diagnosis of disease
EP2225226B1 (en) 2007-12-26 2016-08-17 Critical Outcome Technologies, Inc. Compounds and their use in a method for treatment of cancer
BRPI0920984A2 (pt) 2008-11-21 2017-07-11 Iroko Cardio Llc Método para reduzir trombocitopenia e trombocitopenia associada à mortalidade.
US20120029447A1 (en) 2009-03-18 2012-02-02 Medicure International Inc. Transdermal pharmaceutical preparation and administration of tirofiban
JP2012525336A (ja) * 2009-04-27 2012-10-22 エラン ファーマシューティカルズ，インコーポレイテッド α−４インテグリンのピリジノンアンタゴニスト
EP2552915B1 (en) 2010-04-01 2017-07-19 Critical Outcome Technologies Inc. Compounds for the treatment of hiv
MX352546B (es) 2011-08-17 2017-11-29 Piramal Imaging Sa Compuesto para la union de glicoproteina iib/iiia especifica a plaquetas y su uso para la formacion de imagenes de un trombo.
CN103848775A (zh) * 2012-11-29 2014-06-11 上海信谊药厂有限公司 制备盐酸替罗非班的方法
EP2956461A1 (en) 2013-02-12 2015-12-23 Bayer Pharma Aktiengesellschaft Metal chelate compounds for binding to the platelet specific glycoprotein iib/iiia
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN115181058B (zh) * 2021-04-01 2024-06-11 武汉武药科技有限公司 组合物及其质量控制方法
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1062206B (it) * 1974-02-01 1983-09-20 Rotta Research Lab S P A A S Derivati della tirosina attivi sulla muscolatura liscia
DE2549999A1 (de) * 1975-11-07 1977-05-12 Boehringer Mannheim Gmbh Piperidin-derivate und verfahren zu ihrer herstellung
US4064125A (en) * 1976-10-29 1977-12-20 E. R. Squibb And Sons, Inc. Substituted amides having antiinflammatory activity
US4098889A (en) * 1977-09-01 1978-07-04 The Dow Chemical Company Antithrombotic 2-(aminoalkylthio)-N,N'-p-phenylenebissulfonamides
DE2809377A1 (de) * 1978-03-04 1979-09-13 Boehringer Mannheim Gmbh Phenoxyalkylcarbonsaeure-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
IL60129A0 (en) * 1979-05-23 1980-07-31 Wuelfing J Kg Phenylsulphonamide derivatives,their preparation and pharmaceutical compositions containing them
FR2482528A1 (fr) * 1980-05-14 1981-11-20 Heuliez Henri Holding Vehicule automobile a deux modes de traction, notamment autobus
US5174994A (en) * 1985-11-11 1992-12-29 Leuven Research & Development Vzw Pharmaceutical composition having thrombolytic activity
KR880007441A (ko) * 1986-12-11 1988-08-27 알렌 제이.스피겔 스피로-치환된 글루타르아미드 이뇨제
PH25458A (en) * 1987-08-24 1991-07-01 Eisai Co Ltd Piperidine derivatives, therapeutic, preventive agents
JP2764264B2 (ja) * 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
US5053393A (en) * 1988-07-20 1991-10-01 Monsanto Company Novel platelet-aggregation inhibitor
US4992463A (en) * 1988-07-20 1991-02-12 Monsanto Company Thienyl peptide mimetic compounds which are useful in inhibiting platelet aggregation
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
CA2008116C (en) * 1989-02-23 2001-11-20 Thomas Weller Glycine derivatives
CA1335361C (en) * 1989-05-24 1995-04-25 Andrei Z. Budzynski Thrombus-targeted complexes of plasminogen activator and fibrin fragments
US5023233A (en) * 1989-07-28 1991-06-11 Merck & Co., Inc. Fibrinogen receptor antagonists
US5061693A (en) * 1989-07-28 1991-10-29 Merck & Co., Inc. Fibrinogen receptor antagonists
DE4009506A1 (de) * 1990-03-24 1991-09-26 Hoechst Ag Hydantoinderivate
US5064814A (en) * 1990-04-05 1991-11-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Anti-thrombotic peptide and pseudopeptide derivatives
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
EP0478363A3 (en) 1992-08-19
RU2116296C1 (ru) 1998-07-27
NL990040I2 (nl) 2000-03-01
AU8478291A (en) 1992-04-02
SK102394A3 (en) 1995-04-12
YU30692A (sh) 1995-10-24
ES2133892T3 (es) 1999-09-16
US6040317A (en) 2000-03-21
PT99098A (pt) 1992-08-31
SI9210306B (sl) 1998-06-30
HRP930779B1 (en) 2000-08-31
YU48912B (sh) 2002-11-15
EP0743302B1 (en) 1999-08-04
DE69125235T2 (de) 1997-08-07
BG61810B1 (bg) 1998-06-30
RU94041739A (ru) 1996-08-10
WO1993019046A1 (en) 1993-09-30
EP0478363B1 (en) 1997-03-19
NO913784D0 (no) 1991-09-26
DK0478363T3 (da) 1997-05-12
US5880136A (en) 1999-03-09
NO177702C (no) 1995-11-08
US5658929A (en) 1997-08-19
ATE150454T1 (de) 1997-04-15
CA2052073A1 (en) 1992-03-28
BG99020A (bg) 1995-07-28
LU90505I2 (fr) 2000-03-20
GR3023226T3 (en) 1997-07-30
CY2048B1 (en) 1998-04-30
NL990040I1 (nl) 2000-02-01
US5814643A (en) 1998-09-29
KR100216939B1 (ko) 1999-09-01
EP0478363A2 (en) 1992-04-01
PT99098B (pt) 1999-02-26
SI9210306A (en) 1995-08-31
HK1000509A1 (en) 1998-04-03
IE913383A1 (en) 1992-04-08
JPH04288051A (ja) 1992-10-13
CN1069971A (zh) 1993-03-17
NZ239846A (en) 1994-11-25
CA2052073C (en) 1998-04-14
DE19875054I2 (de) 2007-05-24
NO2000001I2 (no) 2005-09-26
PL172687B1 (pl) 1997-11-28
NO913784L (no) 1992-03-30
JPH09132558A (ja) 1997-05-20
CN1038748C (zh) 1998-06-17
IL99540A (en) 1995-07-31
LV12089B (en) 1998-11-20
ES2100214T3 (es) 1997-06-16
FI914534L (fi) 1992-03-28
US5292756A (en) 1994-03-08
EP0743302A2 (en) 1996-11-20
AU655436B2 (en) 1994-12-22
UA44222C2 (uk) 2002-02-15
SK281233B6 (sk) 2001-01-18
FI20011201A7 (fi) 2001-06-06
IL99540A0 (en) 1992-08-18
EP0743302A3 (en) 1997-03-05
LV12089A (lv) 1998-07-20
RO116621B1 (ro) 2001-04-30
JP2812431B2 (ja) 1998-10-22
JPH0794425B2 (ja) 1995-10-11
NO177702B (no) 1995-07-31
GR3031473T3 (en) 2000-01-31
FI108295B (fi) 2001-12-31
DE69125235D1 (de) 1997-04-24
FI20011201L (fi) 2001-06-06
KR920006313A (ko) 1992-04-27
HRP930779A2 (en) 1997-02-28

Similar Documents

Publication Publication Date Title
FI914534A0 (fi) Nya sulfonamidantagonister foer fibrinogenreceptorer.
Bei et al. BMP4 rescues a non-cell-autonomous function of Msx1 in tooth development
ES2077948T3 (es) Preparacion para el cuidado externo de la piel.
Weber et al. Migration patterns of avian embryonic bone marrow cells and their differentiation to functional T and B cells
DE3788306D1 (de) Cephalosporinderivate, Verfahren zu ihrer Herstellung sowie entsprechende pharmazeutische Präparate.
AR004215A1 (es) Compuestos sulfonamidas, un procedimiento para su preparación, composición farmacéutica que los contiene, compuestos intermediarios, empleo de los compuestos sulfonamidas para la preparacion de un medicamento útil en trastornos asociados con la actividad de la endotelina.
ES8607980A1 (es) Procedimiento para la obtencion de muramilpeptidos
ES8506622A1 (es) Procedimiento para preparar analogos de mevalono-lactona y derivados de los mismos
DE3872171D1 (de) Sebosuppressive zubereitungen.
Graver The polarity of the dental lamina in the regenerating salamander jaw
Yeivin The Synagogue at Korazim
ES2002023A6 (es) Procedimiento para la fabricacion de derivados de 9-(tio-substituido)-4h-pirido(1,2-a)pirimidin-4-ona
ZA955439B (en) Polyalkylpiperidine compounds
Cairncross An" Inconsistency" in" 3 Henry VI"
ES430786A1 (es) Procedimiento para la obtencion de esteres de acidos tria- zolotiazol-fosforicos, -tionodosfoticos, -fosfonicos y tio- nodosfonicos, de efecto insecticida y acaricida.
GR3004107T3 (fi)
Collavo et al. Evidence of an Intrinsic Defect of Lymphocyte Reactivity in AKR Mice.
Baker et al. Notes on Air Evacuation
García et al. Effect of synthetic prostaglandin F2α analogue (cloprostenol) on litter size and weight in a rabbit line selected by growth rate
ES8800675A1 (es) Un procedimiento para preparar tiadiazoles.
UA11490A1 (uk) Спосіб заміщеhhя післярезекційhих дефектів ткаhиhи для порожhиhи рота, язика, ротоглотки та hижhьої щелепи
SU681818A1 (ru) Эфиры α-триалкилсилоксикарбоновых кислот, проявляющие анальгетическую или пролонгирующую гексеналовый наркоз активность

Legal Events

Date Code Title Description
SPCF Supplementary protection certificate application filed

Spc suppl protection certif: L20020012

SPCG Supplementary protection certificate granted

Spc suppl protection certif: L202

Extension date: 20130527

PC Transfer of assignment of patent

Owner name: IROKO CARDIO LLC

Free format text: IROKO CARDIO LLC

MA Patent expired